Functionality of the immune system in patients with chronic hepatitis C: Trial by superinfections and vaccinations

Expert Review of Vaccines

Volumn 6, Issue 4, 2007, Pages 527-537

  Isaguliants, Maria G ^a,b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b D I IVANOVSKY INSTITUTE OF VIROLOGY   (Russian Federation)

Author keywords

Adult vaccine; Antigen presentation; GBV C HGV; HAV; HBV; Hepatitis C virus; HIV; Immune system; Impairment; Influenza; Recall antigen; TTV; Vaccination

Indexed keywords

ANTIRETROVIRUS AGENT; GEN H B VAX; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; INTERFERON; RECOMBINANT HEPATITIS B VACCINE; RIBAVIRIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CHICKENPOX; DENDRITIC CELL; DIPHTHERIA; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS G; HUMAN; IMMUNE SYSTEM; INFECTION RISK; INFECTION SENSITIVITY; INFLUENZA; INNATE IMMUNITY; LIVER TOXICITY; MEASLES; PRIORITY JOURNAL; REVIEW; SCHISTOSOMIASIS; SUPERINFECTION; TETANUS; VACCINATION;

ANIMALS; CD4 LYMPHOCYTE COUNT; DENDRITIC CELLS; HEALTH STATUS; HEPATITIS A VACCINES; HEPATITIS B VACCINES; HEPATITIS C, CHRONIC; HUMANS; IMMUNE SYSTEM; IMMUNITY, NATURAL; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC MEMORY; INFLUENZA VACCINES; T-LYMPHOCYTES; VACCINATION; VIRUS DISEASES;

EID: 34548017160     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.4.527     Document Type: Review

References (114)

1. Rook GA, Stanford JL. Give us this day our daily germs. Immunol. Today 19(3), 113-116 (1998). •• Reviews the role of germs and the immune response to germs in developing healthy immune system, a theory gaining more and more credence as more evidence emerges.
2. Kim SK, Cornberg M, Wang XZ, Chen HD, Selin LK, Welsh RM. Private specificities of CD8 T cell responses control patterns of heterologous immunity. J. Exp. Med. 201(4), 523-533 (2005).
3. Welsh RM, Kim SK, Cornberg M, Clute SC, Selin LK, Naumov YN. The privacy of T cell memory to viruses. Curr. Top. Microbiol. Immunol. 311, 117-153 (2006). •• Describes how the immune response against previously encountered pathogens shapes the immune response against new ones. Such heterologous immunity can deviate from the normal immune response and result in either beneficial or harmful effects to the host.
4. Ostler T, Pircher H, Ehl S. "Bystander" recruitment of systemic memory T cells delays the immune response to respiratory virus infection. Eur. J. Immunol. 33(7), 1839-1848 (2003).
5. Naniche D, Yeh A, Eto D, Manchester M, Friedman RM, Oldstone MB. Evasion of host defenses by measles virus: wild-type measles virus infection interferes with induction of α/β interferon production. J. Virol. 74(16), 7478-7484 (2000).
6. Moss WJ, Ota MO, Griffin DE. Measles: immune suppression and immune responses. Int. J. Biochem. Cell Biol. 36(8), 1380-1385 (2004). • Describes mechanism of prolonged immune suppression by measles along with consequences of subsequent infections and vaccinations.
7. Desai HN, Strashoon J, Wesley A. Cell-mediated immunity in measles using the leucocyte migration test. Int. Arch. Allergy Appl. Immunol. 57(4), 312-316 (1978).
8. Khan N, Hislop A, Gudgeon N et al. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J. Immunol. 173(12), 7481-7489 (2004).
9. Isaguliants MG. Hepatitis C virus clearance: the enigma of failure despite an impeccable survival strategy. Curr. Pharm. Biotechnol. 4(3), 169-183 (2003).
10. Pal S, Sullivan DG, Kim S et al. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology 130(4), 1107-1116 (2006). •• Research paper documenting the major contribution of lymphoid replication to hepatitis C virus (HCV) viremia.
11. Kondo Y, Sung VM, Machida K, Liu M, Lai MM. Hepatitis C virus infects T cells and affects interferon-γ signaling in T cell lines. Virology 361(1), 161-173 (2007).
12. Praditpornsilpa K, Eiam-Ong S, Sitprija V. Hepatitis virus and kidney. Singapore Med. J. 37(6), 639-644 (1996).
13. Matsumori A, Matoba Y, Sasayama S. Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 92(9), 2519-2525 (1995).
14. Kanazawa H, Yoshikawa J. Alterations in T-lymphocyte subsets in the airways of asthmatic patients with active hepatitis C virus infection. Respiration 73(3), 318-323 (2006).
15. Forton DM, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. J. Viral Hepat. 10(2), 81-86 (2003).
16. Berk DR, Mallory SB, Keeffe EB, Ahmed A. Dermatologic disorders associated with chronic hepatitis C: effect of interferon therapy. Clin. Gastroenterol. Hepatol. 5(2), 142-151 (2007).
17. Weng WK, Levy S. Hepatitis C virus (HCV) and lymphomagenesis. Leuk. Lymphoma 44(7), 1113-1120 (2003).
18. Longman RS, Talal AH, Jacobson IM, Rice CM, Albert ML. Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J. Infect. Dis. 192(3), 497-503 (2005).
19. Kanto T, Inoue M, Miyazaki M et al. Impaired function of dendritic cells circulating in patients infected with hepatitis C virus who have persistently normal alanine aminotransferase levels. Intervirology 49(1-2), 58-63 (2006).
20. Matsui M, Moriya O, Abdel-Aziz N, Matsuura Y, Miyamura T, Akatsuka T. Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus. Vaccine 21(3-4), 211-220 (2002).
21. Sapp M, Engelmayer J, Larsson M, Granelli-Piperno A, Steinman R, Bhardwaj N. Dendritic cells generated from blood monocytes of HIV-1 patients are not infected and act as competent antigen presenting cells eliciting potent T-cell responses. Immunol. Lett. 66(1-3), 121-128 (1999).
22. Larsson M, Babcock E, Grakoui A et al. Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus. J. Virol. 78(12), 6151-6161 (2004).
23. Auffermann-Gretzinger S, Keeffe EB, Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 97(10), 3171-3176 (2001).
24. Dolganiuc A, Kodys K, Kopasz A et al. Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J. Immunol. 170(11), 5615-5624 (2003).
25. Sarobe P, Lasarte JJ, Zabaleta A et al. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J. Virol. 77(20), 10862-10871 (2003).
26. Anthony DD, Yonkers NL, Post AB et al. Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. J. Immunol. 172(8), 4907-4916 (2004).
27. Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 120(2), 512-524 (2001).
28. Kanto T, Hayashi N, Takehara T et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J. Immunol. 162(9), 5584-5591 (1999).
29. Szabo G, Dolganiuc A. Subversion of plasmacytoid and myeloid dendritic cell functions in chronic HCV infection. Immunobiology 210(2-4), 237-247 (2005).
30. Kakumu S, Okumura A, Ishikawa T, Iwata K, Yano M, Yoshioka K. Production of interleukins 10 and 12 by peripheral blood mononuclear cells (PBMC) in chronic hepatitis C virus (HCV) infection. Clin. Exp. Immunol. 108(1), 138-143 (1997).
31. +) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J. Virol. 76(10), 5062-5070 (2002). • Experimental model demonstrating that expression of HCV structural antigens in infected dendritic cells (DCs) disturbs their antigen-presenting function.
32. Murakami H, Akbar SM, Matsui H, Horiike N, Onji M. Decreased interferon-α production and impaired T helper 1 polarization by dendritic cells from patients with chronic hepatitis C. Clin. Exp. Immunol. 137(3), 559-565 (2004).
33. Morita K, Fukuda Y, Nakano I, Katano Y, Hayakawa T. Peripheral lymphocyte subsets vary with stage of hepatitis C virus-associated liver disease. Hepatogastroenterology 52(66), 1803-1808 (2005).
34. Rosa D, Saletti G, De Gregorio E et al. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc. Natl Acad. Sci. USA 102(51), 18544-18549 (2005).
35. Polyak SJ, Khabar KS, Rezeiq M, Gretch DR. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J. Virol. 75(13), 6209-6211 (2001).
36. Antonaci S, Piazzolla G, Napoli N, Vella FS, Fiore G, Schiraldi O. Relationship between T lymphocyte responsiveness and T-helper1/T-helper2 type cytokine release in chronic hepatitis C: a critical reappraisal. Microbios 106(415), 203-212 (2001).
37. + T helper cells in chronic HCV infection. Hepatology 41(5), 1019-1028 (2005).
38. Morita K, Fukuda Y, Nakano I, Katano Y, Hayakawa T. Peripheral lymphocyte subsets vary with stage of hepatitis C virus-associated liver disease. Hepatogastroenterology 52(66), 1803-1808 (2005).
39. Mondelli MU, Barnaba V. Viral and host immune regulatory mechanisms in hepatitis C virus infection. Eur. J. Gastroenterol. Hepatol. 18(4), 327-331 (2006).
40. Racanelli V, Rehermann B. Hepatitis C virus infection: when silence is deception. Trends Immunol. 24(8), 456-464 (2003). •• Excellent review describing the mechanisms of primary failure of the HCV-specific T-cell response, active HCV 'counter-attacks' on several components of the cellular immune response and characterizing immunity to HCV as not sterilizing, but protecting against development of persistent infection on the re-exposure to the virus.
41. Ferrari C. T and B cells in hepatitis C virus control: what they do and when they fail. Gastroenterology 132(2), 801-805 (2007).
42. Kaplan DE, Sugimoto K, Newton K et al. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology 132(2), 654-666 (2007).
43. Valdez H, Anthony D, Farukhi F et al. Immune responses to hepatitis C and nonhepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients. AIDS 14(15), 2239-46 (200).
44. + T cells by flow cytometry: correlation with clinical disease stages. Hepatology 35(1), 190-198 (2002).
45. England K, Thorne C, Newell ML. Vertically acquired paediatric coinfection with HIV and hepatitis C virus. Lancet Infect. Dis. 6(2), 83-90 (2006). • Unique story of HIV, HCV and mixed HIV-HCV transmission and disease progression in pediatric patients.
46. Al-Harthi L, Voris J, Du W et al. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J. Infect. Dis. 193(9), 1202-1210 (2006).
47. Graham CS, Koziel MJ. Why should hepatitis C affect immune reconstitution in HIV-1-infected patients? Lancet 356(9245), 1865-1866 (2000). •• Analytical review describing how HCV infection influences CD4 cell kinetics in HIV-HCV patients on highly active antiretroviral therapy (HAART) as a basis for better therapeutic options for dually infected patients.
48. Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356(9244), 1800-1805 (2000).
49. Carlos Martin J, Castilla J, Lopez M, Arranz R, Gonzalez-Lahoz J, Soriano V. Impact of chronic hepatitis C on HIV-1 disease progression. HIV Clin. Trials 5(3), 125-131 (2004). • Large cohort study unambiguously demonstrating a significant association between HCV infection and CD4 cell counts in HIV-infected individuals on HAART.
50. Antonucci G, Girardi E, Cozzi-Lepri A et al; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Clin. Infect. Dis. 40(12), E101-E109 (2005).
51. Nunez M, Soriano V. Current concepts in the management and treatment of hepatitis C in HIV-infected patients. Ann. Hepatol. 4(3), 151-160 (2005).
52. Yoo TW, Donfield S, Lail A, Lynn HS, Daar ES; Hemophilia Growth and Development Study. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J. Infect. Dis. 191(1), 4-10 (2005).
53. Sagnelli E, Coppola N, Messina V et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 36(5), 1285-1291 (2002).
54. Gaeta GB, Stornaiuolo G, Precone DF et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J. Hepatol. 39(6), 1036-1041 (2003).
55. Wietzke P, Schott P, Braun F, Mihm S, Ramadori G. Clearance of HCV RNA in a chronic hepatitis C virus-infected patient during acute hepatitis B virus superinfection. Liver 19(4), 348-353 (1999). • First evidence that acute hepatitis B virus (HBV) infection leads to spontaneous HCV clearance by stimulating a specific immune response against HCV as well as triggering nonspecific defense mechanisms which finally eliminate both viruses.
56. Liaw YF, Yeh CT, Tsai SL. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am. J. Gastroenterol. 95(10), 2978-2980 (2000).
57. Gruener NH, Jung MC, Ulsenheimer A et al. Hepatitis C virus eradication associated with hepatitis B virus superinfection and development of a hepatitis B virus specific T cell response. J. Hepatol. 37(6), 866-869 (2002).
58. Pramoolsinsap C, Poovorawan Y, Hirsch P, Busagorn N, Attamasirikul K. Acute, hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV. Ann. Trop. Med. Parasitol. 93(7), 745-751 (1999).
59. Vento S. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. J. Viral Hepat. 7(Suppl. 1), 7-8 (2000).
60. Shim M, Khaykis I, Park J, Bini EJ. Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination. Hepatology 42(3), 688-695 (2005).
61. Deterding K, Tegtmeyer B, Cornberg M et al. Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV. J. Hepatol. 45(6), 770-778 (2006). • Argues against a fulminant course of hepatitis A in chronic hepatitis C patients and actually shows that the biochemical parameters of liver disease are lower in anti-HCV-positive hepatitis A patients, and that hepatitis A virus superinfection in chronic hepatitis C is associated with decreased HCV RNA replication, eventually leading to recovery from HCV.
62. Sagnelli E, Coppola N, Pisaturo M et al. Clinical and virological improvement of hepatitis B virus-related or hepatitis C virus-related chronic hepatitis with concomitant hepatitis A virus infection. Clin. Infect. Dis. 42(11), 1536-1543 (2006).
63. Bradley DW, Maynard JE, McCaustland KA, Murphy BL, Cook EH, Ebert JW. Non-A, non-B hepatitis in chimpanzees: interference with acute hepatitis A virus and chronic hepatitis B virus infections. J. Med. Virol. 11(3), 207-213 (1983).
64. Pramoolsinsap C, Attamasirul K, Busagorn N et al. Susceptibility to hepatitis A virus infection among chronic liver disease patients and healthy blood donors in Thailand. Southeast Asian J. Trop. Med. Public Health 30(1), 91-95 (1999).
65. Hamid SS, Atiq M, Shehzad F et al. Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology 36(2), 474-478 (2002).
66. Rambusch EG, Wedemeyer H, Tillmann HL, Heringlake S, Manns MP. Significance of coinfection with hepatitis G virus for chronic hepatitis C - a review of the literature. Z. Gastroenterol. 36(1), 41-53 (1998).
67. Myers RP, Thibault V, Poynard T. The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C. J. Viral Hepat. 10(2), 103-110 (2003).
68. Francesconi R, Giostra F, Ballardini G et al. Clinical implications of GBV-C/HGV infection in patients with "HCV-related" chronic hepatitis. J. Hepatol. 26(6), 1165-1172 (1997).
69. Chu C, Hwang S, Luo J et al. Clinical, virological, immunological, and pathological significance of GB virus C/hepatitis G infection in patients with chronic hepatitis C. Hepatol. Res. 19(3), 225-236 (2001).
70. Yang JF, Dai CY, Chuang WL et al. Prevalence and clinical significance of HGV/GBV-C infection in patients with chronic hepatitis B or C. Jpn J. Infect. Dis. 59(1), 25-30 (2006).
71. Kaya S, Cicioglu Aridogan B, Demirci M. The prevalence of hepatitis G virus in patients with hepatitis B and C virus infections. Mikrobiyol. Bul. 38(4), 421-427 (2004).
72. Komatsu H, Fujisawa T, Inui A et al. GBV-C/HGV infection in children with chronic hepatitis C. J. Med. Virol. 59(2), 154-159 (1999).
73. Hardikar W, Moaven LD, Bowden DS, Locarnini SA, Smith AL. Hepatitis G: viroprevalence and seroconversion in a high-risk group of children. J. Viral Hepat. 6(4), 337-341 (1999).
74. Tacke M, Schmolke S, Schlueter V et al. Humoral immune response to the E2 protein of hepatitis G virus is associated with long-term recovery from infection and reveals a high frequency of hepatitis G virus exposure among healthy blood donors. Hepatology 26(6), 1626-1633 (1997).
75. Yzebe D, Xueref S, Baratin D, Bouletreau A, Fabry J, Vanhems P. TT virus. A review of the literature. Panminerva Med. 44(3), 167-177 (2002).
76. Moen EM, Sagedal S, Bjoro K, Degre M, Opstad PK, Grinde B. Effect of immune modulation on TT virus (TTV) and TTV-like-mini-virus (TLMV) viremia. J. Med. Virol. 70(1), 177-182 (2003).
77. Christensen JK, Eugen-Olsen J, Slrensen M et al. Prevalence and prognostic significance of infection with TT virus in patients infected with human immunodeficiency virus. J. Infect. Dis. 181(5), 1796-1799 (2000).
78. Shang D, Lin YH, Rigopoulou I, Chen B, Alexander GJ, Allain JP. Detection of TT virus DNA in patients with liver disease and recipients of liver transplant. J. Med. Virol. 61(4), 455-461 (2000).
79. Shibayama T, Masuda G, Ajisawa A et al. Inverse relationship between the titre of TT virus DNA and the CD4 cell count in patients infected with HIV. AIDS 15(5), 563-570 (2001).
80. Touinssi M, Gallian P, Biagini P et al. TT virus infection: prevalence of elevated viraemia and arguments for the immune control of viral load. J. Clin. Virol. 21(2), 135-141 (2001).
81. Par A, Takacs M, Brojnas J et al. Co-infections with hepatitis G and TT virus in patients with chronic hepatitis C in Hungary. Acta Microbiol. Immunol. Hung. 51(4), 437-447 (2004).
82. Al-Moslih MI, Abuodeh RO, Hu YW. Detection and genotyping of TT virus in healthy and subjects with HBV or HCV in different populations in the United Arab Emirates. J. Med. Virol. 72(3), 502-508 (2004).
83. Ali S, van Pelt JF, Verslype C, Nevens F, Fevery J, Yap SH. TT virus infection in acute and chronic liver diseases and in patients regularly receiving blood products in Belgium. Acta Gastroenterol. Belg. 67(2), 161-165 (2004).
84. Asselah T, Boudjema H, Francoz C et al. Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management. Gastroenterol. Clin. Biol. 30(11), 1281-1295 (2006).
85. Tokita H, Murai S, Kamitsukasa H et al. High TT virus load as an independent factor associated with the occurrence of hepatocellular carcinoma among patients with hepatitis C virus-related chronic liver disease. J. Med. Virol. 67(4), 501-509 (2002).
86. Kamal SM, Bianchi L, Al Tawil A et al. Specific cellular immune response and cytokine patterns in patients coinfected with hepatitis C virus and Schistosoma mansoni. J. Infect. Dis. 184(8), 972-982 (2001).
87. Large MK, Kittlesen DJ, Hahn YS. Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J. Immunol. 162(2), 931-938 (1999).
88. Wong V, Wreghitt TG, Alexander GJ. Prospective study of hepatitis B vaccination in patients with chronic hepatitis C. Br. Med. J. 312(7042), 1336-1337 (1996).
89. Zuckerman JN. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J. Med. Virol. 78(2), 169-177 (2006). •• Excellent review of the strategies of vaccination against HBV.
90. Lee SD, Chan CY, Yu MI, Lu RH, Chang FY, Lo KJ. Hepatitis B vaccination in patients with chronic hepatitis C. J. Med. Virol. 59(4), 463-468 (1999).
91. Wiedmann M, Liebert UG, Oesen U et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 31(1), 230-234 (2000).
92. Idilman R, De MN, Colantoni A, Nadir A, Van Thiel DH. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. Am. J. Gastroenterol. 97(2), 435-439 (2002).
93. Leroy V, Bourliere M, Durand M et al. The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C virus viral load in patients with chronic hepatitis C: a case-control study. Eur. J. Gastroenterol. Hepatol. 14(5), 485-489 (2002). • Results suggest that in patients with CHC, HCV load may negatively influence the response to HBV vaccine.
94. Elefsiniotis IS, Vezali E, Kamposioras K et al. Immunogenicity of recombinant hepatitis B vaccine in treatment-naive and treatment-experienced chronic hepatitis C patients: the effect of pegylated interferon plus ribavirin treatment. World J. Gastroenterol. 12(27), 4420-4424 (2006).
95. Mattos AA, Gomes EB, Tovo CV, Alexandre CO, Remiao JO. Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus. Arq. Gastroenterol. 41(3), 180-184 (2004).
96. Jacobs RJ, Koff RS, Meyerhoff AS. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Am. J. Gastroenterol. 97(2), 427-434 (2002).
97. Keeffe EB, Iwarson S, McMahon BJ et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 27(3), 881-886 (1998).
98. Lee SD, Chan CY, Yu MI et al. Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease. J. Med. Virol. 52(2), 215-218 (1997).
99. Majda-Stanislawska E, Bednarek M, Kuydowicz J. Immunogenicity of inactivated hepatitis A vaccine in children with chronic liver disease. Pediatr. Infect. Dis. J. 23(6), 571-574 (2004).
100. Kallinowski B, Jilg W, Buchholz L, StremmelW, Engler S. Immunogenicity of an accelerated vaccination regime with a combined hepatitis A/B vaccine in patients with chronic hepatitis C. Z. Gastroenterol. 41(10), 983-990 (2003).
101. Duchini A, Viernes ME, Nyberg LM, Hendry RM, Pockros PJ. Hepatic decompensation in patients with cirrhosis during infection with influenza A. Arch. Intern. Med. 160(1), 113-115 (2000).
102. Duchini A, Hendry RM, Nyberg LM, Viernes ME, Pockros PJ. Immune response to influenza vaccine in adult liver transplant recipients. Liver Transpl. 7(4), 311-313 (2001).
103. De Bac C, Stroffolini T, Gaeta GB, Taliani G, Giusti G. Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: a multicenter Italian study. Hepatology 20(5), 1225-1230 (1994).
104. Gaeta GB, Stornaiuolo G, Precone DF, Amendola A, Zanetti AR. Immunogenicity and safety of an adjuvanted influenza vaccine in patients with decompensated cirrhosis. Vaccine 20(Suppl. 5), B33-B35 (2002). • One of the first papers evaluating the efficacy of common vaccines targeted against liver-unrelated diseases in patients with CHC.
105. Navasa M, Rodes J. Bacterial infections in cirrhosis. Liver Int. 24(4), 277-280 (2004).
106. Ghassemi S, Garcia-Tsao G. Prevention and treatment of infections in patients with cirrhosis. Best Pract. Res. Clin. Gastroenterol. 21(1), 77-93 (2007).
107. + T cells activated within the lymph nodes are capable of mediating hepatitis, cells undergoing primary activation within the liver exhibit shortened half-life and defective cytotoxic function and do not mediate hepatocellular injury.
108. Warren A, Le Couteur DG, Fraser R, Bowen DG, McCaughan GW, Bertolino P. T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. Hepatology 44(5), 1182-1190 (2006).
109. Carithers RL Jr, Sugano D, Bayliss M. Health assessment for chronic HCV infection: results of quality of life. Dig. Dis. Sci. 41(Suppl. 12), 75S-80S (1996).
110. Strauss E, Dias Teixeira MC. Quality of life in hepatitis C. Liver Int. 26(7), 755-765 (2006).
111. Arguedas MR, McGuire BM, Fallon MB. Implementation of vaccination in patients with cirrhosis. Dig. Dis. Sci. 47(2), 384-387 (2002).
112. Potthoff A, Sarhaddar J, Wiegand J et al. Spontaneous resolution of chronic hepatitis C virus infection after antiviral treatment and relapse. Hepatol. Res. 31(1), 18-23 (2005).
113. Epidemiology and Prevention of Viral Hepatitis A to E: an overview. Hepatitis Branch. Centers for Disease Control and Prevention http://ftp.cdc.gov/pub/infectious_diseases/hepatitis/slides/technote.txt
114. Statistics about hepatitis A www.wrongdiagnosis.com/h/hepatitis_a/stats. htm